Activity

FDA Approves Dupixent® for Chronic Rhinosinusitis With Nasal Polyps

The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.

AAFA Elevates Patient Voice in ICER Review of New Peanut Allergy Treatments

On June 11, 2019, in Oakland, California, the Institute for Clinical and Economic Review (ICER) and its California Technology Assessment Forum (CTAF) met to assess the clinical effectiveness and value of treatments for peanut allergy. The review examined two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT).

AAFA Applauds DOT Warning About Denial of Preboarding to Family With Food Allergies

AAFA applauds the warning the U.S. Department of Transportation (USDOT) issued to American Airlines in response to American Airline’s denial of the right to pre-board a family of a child with food allergies. However, AAFA calls on the USDOT and Congress to take even stronger actions to protect the rights of airline passengers with allergies and all disabilities.

Post
×
×
×
×